First Author: N.Menassa UK
Co Author(s): R. Edirisinghe S. Jalpota 0 0 0 0 0 0 0 0 0
Back to previous
To assess outcomes of intravitreal (IVT) Ranibizumab (Lucentis®) injections for treating patients with diabetic macular oedema (DMO). To compare local results with the published data and address possible areas of improvement.
Department of Ophthalmology, Northampton General Hospital, UK
Retrospective data analysis of 59 consecutive eyes following a loading dose of 3 IVT Ranibizumab injections. Outcome measures were the mean change of logMAR visual acuity (VA) with the ETDRS chart and mean change of central retinal thickness (CRT) using Optical Coherence Tomography (3D OCT-2000, Topcon, UK). The local results were compared to the RESTORE trial and Diabetic Retinopathy Clinical Research Network Protocol I (DRCR.net).
After the initial 3 IVT Ranibizumab injections the mean gain of VA +4.96 ± 9.21 letters compared to +6.1 and +9 letters in RESTORE and DRCR.net trials respectively after 1 year. The mean CRT reduction was -109.5±93.6 micrometres compared to -118.7 micrometres in RESTORE.
The initial local results of intravitreal Ranibizumab injections for treatment of DMO are promising. A loading dose of 4 IVT injections in addition to prompt/deferred grid laser treatment similar to the DRCR.net protocol might help stabilise VA and CRT further. The results need to be re-analysed at 12 and 24 months to assess the long-term outcomes of the treatment.